TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03134781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT workout
Description: A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT workout - Detraining
Description: A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control - No training
Description: No training was performed during a 40-week period. Participation only in measurements.
Study: NCT01274520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Medtronic Portable Bypass System (PBS®)
Description: Will be used for machine perfusion of liver grafts.
Study: NCT04318600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human amniotic mesenchymal stem cell
Description: human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
Study: NCT00652886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: Tablets, 10mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrin
Description: tablets, 10mg, single-dose
Study: NCT03897842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve Cardiovascular System
Description: The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
Study: NCT01374178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered subcutaneously
Study: NCT01349764

Intervention type: DRUG
Intervention: Vitamin D3
Study: NCT03187808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single thoracic manipulation
Description: The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single thoracic manipulation
Description: The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Special massage technique (RT technique)
Description: The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
Study: NCT03094715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).

Intervention type: OTHER
Group type: OTHER
Intervention: Best medical care
Description: Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
Study: NCT04245813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary educational program
Description: Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
Study: NCT01156857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001, placebo
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001, progestin
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
Study: NCT01302340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delta-THC
Description: Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delta-THC
Description: In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
Study: NCT02666079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LightPath® Imaging System.
Description: Intra-operative use of the LightPath® Imaging System.
Study: NCT01442545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 / MTX
Description: Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
Study: NCT02906644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Study: NCT03529201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: administered by PCA
Study: NCT04094675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Use of sirolimus 2 mg by mouth daily for 1 year
Study: NCT01508975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Rice, Brown Rice, Glucose
Description: white rice, brown rice, glucose
Study: NCT05268159

Intervention type: OTHER
Intervention: Cognitive assessment
Description: Assessment of unilateral spatial neglect, attention, executive functions and memory
Study: NCT04700358

Intervention type: OTHER
Intervention: Blood sampling
Description: Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)

Intervention type: OTHER
Intervention: Blood sampling
Description: Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)
Study: NCT03253887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol-lock
Description: This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
Study: NCT03529201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: administered by PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalational anesthetic during GA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalational anesthetic during GA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: painkiller during GA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: painkiller during GA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: muscle relaxant during GA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: muscle relaxant during GA
Study: NCT01329640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide
Description: 1. Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~2. Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks
Study: NCT01312090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy
Description: Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling and behavioral therapy for weight loss
Description: Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
Study: NCT02166658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
Study: NCT02906644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Study: NCT03624660

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HR-A
Description: The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks.
Study: NCT00439036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug Counseling
Study: NCT02501200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391
Description: Investigational product is prescribed to all of randomized subjects for two times.
Study: NCT02906644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo lorcaserin
Study: NCT03624660

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HR-B
Description: The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks.
Study: NCT03322488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistulodesis
Description: Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistulodesis
Description: Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline).
Study: NCT04306874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Max Protein
Description: Liquid shake with 30 g protein per serving
Study: NCT01210365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diurisa®
Description: Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasix ®
Description: One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
Study: NCT05440279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: digital patient support
Description: Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~1. electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~2. possibility to set personal adherence goals every week,~3. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~4. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring.
Study: NCT00873509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
Study: NCT02501200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391
Description: Investigational product is prescribed to all of randomized subjects for two times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastatin and Ezetimibe combination therapy
Description: Investigational products are prescribed to all of radomized subjects for two times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastatin and Ezetimibe combination therapy
Description: Investigational products are prescribed to all of radomized subjects for two times.
Study: NCT03706300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg
Study: NCT01245270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberry capsule first, then control cap
Description: Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control capsule first then bilberry cap
Description: Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time.